Sarepta plans to sell $225M of stock to support clinical trials, drug commercialization

Following the FDA's approval Monday of its muscular dystrophy drug, Cambridge, Mass.-based Sarepta Therapeutics plans to sell up to $255 million of stock and use the proceeds to fund clinical trials, drug commercialization and manufacturing, according to The Wall Street Journal.

The FDA approved eteplirsen, Sarepta's treatment for Duchenne muscular dystrophy, Monday after a long and contentious internal debate. After news of the approval, the company's shares skyrocketed 74 percent to $48.94 Monday. Sarepta stock rose 14 percent more Tuesday when the company received favorable patent decisions resolving a dispute with BioMarin Pharmaceutical. On Wednesday Sarepta's stock rose 0.9 percent and then another 0.7 percent after hours to $56.59 percent, according to the report.

The company filed a shelf registration in February for the potential sale of its securities, according to the report. Underwriters for the stock include J.P. Morgan, Goldman Sachs and Credit Suisse.

In June, Sarepta held a smaller stock sale of 2.1 million shares for $17.84 each, according to the report.

More articles on supply chain:
Trucking volumes rebound in August
5 reasons insurance claims should include UDIs
Sarepta's drug approval: The rise of consumer input or the fall of drug standards?

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars